...
首页> 外文期刊>BMC Infectious Diseases >Cytomegalovirus infection and outcome in immunocompetent patients in the intensive care unit: a systematic review and meta-analysis
【24h】

Cytomegalovirus infection and outcome in immunocompetent patients in the intensive care unit: a systematic review and meta-analysis

机译:密集护理单位免疫活性患者的巨细胞病毒感染和结果:系统审查和荟萃分析

获取原文

摘要

Cytomegalovirus (CMV) infection is common in immunocompetent patients in intensive care units (ICUs). However, whether CMV infection or CMV reactivation contributes to mortality of immunocompetent patients remains unclear. A literature search was conducted for relevant studies published before May 30, 2016. Studies reporting on CMV infection in immunocompetent patients in ICUs and containing 2?×?2 tables on CMV results and all-cause mortality were included. Eighteen studies involving 2398 immunocompetent patients admitted to ICUs were included in the meta-analysis. The overall rate of CMV infection was 27% (95%CI 22-34%, I2?=?89%, n?=?2398) and the CMV reactivation was 31% (95%CI 24-39%, I2?=?74%, n?=?666). The odds ratio (OR) for all-cause mortality among patients with CMV infection, compared with those without infection, was 2.16 (95%CI 1.70-2.74, I2?=?10%, n?=?2239). Moreover, upon exclusion of studies in which antiviral treatment was possibly or definitely provided to some patients, the association of mortality rate with CMV infection was also statistically significant (OR: 1.69, 95%CI 1.01-2.83, I2?=?37%, n?=?912,). For CMV seropositive patients, the OR for mortality in patients with CMV reactivation as compared with patients without CMV reactivation was 1.72 (95%CI 1.04-2.85, I2?=?29%, n?=?664). Patients with CMV infection required significantly longer mechanical ventilation (mean difference (MD): 9?days (95% CI 5-14, I2?=?81%, n?=?875)) and longer duration of ICU stay (MD: 12?days (95% CI 7-17, I2?=?70%, n?=?949)) than patients without CMV infection. When analysis was limited to detection in blood, CMV infection without antiviral drug treatment or reactivation was not significantly associated with higher mortality (OR: 1.69, 95%CI 0.81-3.54, I2?=?52%, n?=?722; OR: 1.49, I2?=?63%, n?=?469). Critically ill patients without immunosuppression admitted to ICUs show a high rate of CMV infection. CMV infection during the natural unaltered course or reactivation in critically ill patients is associated with increased mortality, but have no effect on mortality when CMV in blood. More studies are needed to clarify the impact of CMV infection on clinical outcomes in those patients.
机译:巨细胞病毒(CMV)感染在密集护理单位(ICU)中的免疫活性患者中常见。然而,CMV感染或CMV再激活是否有助于免疫活性患者的死亡率仍然尚不清楚。在2016年5月30日之前发表的相关研究进行了文献搜索。包括CMV结果和含有2次免疫因素患者CMV感染的研究报告,包括CMV结果和全导致死亡率。涉及2398名涉及ICU的2398名免疫活性患者的18项研究被列入META分析。 CMV感染的总体速率为27%(95%CI 22-34%,I2?= 89%,n?= 2398),CMV再活化为31%(95%CI 24-39%,I2?= ?74%,n?=?666)。与没有感染的人相比,CMV感染患者的患者的含量比(或)的差异(或)为2.16(95%CI 1.70-2.74,I2?= 10%,n?= 2239)。此外,在排除可能或绝对向某些患者提供抗病毒治疗的研究之后,对CMV感染的死亡率结合也存在统计学意义(或:1.69,95%CI 1.01-2.83,I2?= 37%, n?=?912,)。对于CMV血清阳性患者,与没有CMV再激活的患者相比,CMV再激活患者的死亡率为1.72(95%CI 1.04-2.85,I2?= 29%,N?= 664)。 CMV感染的患者需要明显更长的机械通气(平均差异(MD):9?天(95%CI 5-14,I2?=?81%,N?=?875))等ICU Stay的持续时间(MD: 12?天(95%CI 7-17,I2?= 70%,n?=α949))比没有CMV感染的患者。当分析限于血液中的检测时,没有抗病毒药物治疗或重新激活的CMV感染与较高的死亡率没有显着相关(或:1.69,95%CI 0.81-3.54,I2?= 52%,N?=?722;或:1.49,I2?=?63%,n?= 469)。没有免疫抑制的患者患者患有ICU的免疫抑制患者显示出高率的CMV感染。 CMV感染在天然未改变的过程中或重新激活的患者中的重新激活与增加的死亡率增加,但在血液中CMV时对死亡率没有影响。需要更多的研究来阐明CMV感染对这些患者临床结果的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号